SCHEDULE 13G: Immunocore Holdings plc Insider Discloses 8.2% Beneficial Ownership Stake
Beneficial Ownership Disclosure
Dr. Bahija Jallal, a key individual at Immunocore Holdings plc, has disclosed beneficial ownership of 8.2% of the company's ordinary shares as of December 31, 2024.
Summary
- The filing is a Schedule 13G, indicating a passive beneficial ownership stake in Immunocore Holdings plc.
- The reporting person is Bahija Jallal, Ph.D., a U.S. citizen.
- As of December 31, 2024, Dr. Jallal beneficially owned 4,493,139 ordinary shares of Immunocore Holdings plc.
- This ownership represents 8.2% of the company's total ordinary shares outstanding.
- The beneficially owned shares consist entirely of ordinary shares underlying outstanding options held by Dr. Jallal that are or will be exercisable within 60 days of December 31, 2024.
- The percentage of class is based on 50,032,770 ordinary shares outstanding as of October 31, 2024, as reported by Immunocore Holdings plc in its Form 10-Q filed on November 6, 2024.
Sentiment
Score: 5
Explanation: This filing is a standard disclosure of beneficial ownership and does not contain information that would inherently indicate positive or negative sentiment regarding the company's performance or outlook. The significant insider stake could be seen as a neutral to slightly positive signal.
Positives
- The disclosure of a significant 8.2% beneficial ownership by an insider like Dr. Bahija Jallal can be viewed positively by investors, as it indicates strong alignment of interests between management and shareholders.
Future Outlook
This document is a disclosure of beneficial ownership and does not contain any forward-looking statements or guidance regarding the company's future outlook.
Industry Context
This filing is a standard regulatory disclosure of a significant ownership stake by an individual, likely an insider, in a publicly traded biotechnology or pharmaceutical company. It provides transparency regarding the ownership structure but does not offer insights into broader industry trends or competitive landscape.
Stakeholder Impact
- Shareholders: Provides transparency regarding significant insider ownership, which can influence investor confidence and perception of management alignment.
Key Dates
| Date | Description |
|---|---|
| 2024-10-31 | Date of total ordinary shares outstanding (50,032,770) used for percentage calculation, as reported in the Issuer's Form 10-Q. |
| 2024-11-06 | Date Immunocore Holdings plc filed its Form 10-Q for the quarter ended September 30, 2024. |
| 2024-12-31 | Date of event which requires the filing of this statement, reflecting Dr. Jallal's beneficial ownership. |
| 2025-02-14 | Date the Schedule 13G statement was filed. |
Keywords
Immunocore Holdings plc, Bahija Jallal, Schedule 13G, beneficial ownership, insider ownership, ordinary shares, stock options, SEC filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.